The COAPT Trial

The COAPT Trial is a trial in the U.S. and Canada that will study an investigational device in patients who have functional mitral regurgitation and are not appropriate candidates for mitral valve surgery.

Patients will be randomly assigned to a Device Group or Control Group. Both groups will receive the current recommended treatment, also known as the standard of care. For patients with mitral regurgitation who are not appropriate candidates for mitral valve surgery, the standard of care may include one or more of these therapies:

  • Medications
  • Implantation of a pacemaker or cardiac resynchronization therapy, devices that deliver electrical impulses to help the heart beat normally
  • Treatments for coronary artery disease

The COAPT Trial will study approximately 610 patients at as many as 100 medical centers in the U.S and Canada.

Learn more about the device and control groups »